Teclistamab-cqyv is a T-cell-engaging bispecific antibody that targets multiple myeloma cells via the B-cell maturation ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

The first, MGUS, is considered the earliest precursor of multiple myeloma, before symptoms are present. This plasma cell disorder is benign, does not require treatment, and carries a risk of 1% ...

In the beginning, when I was very young, I was more interested in acute leukaemia and the suffering of young people. When I ...

Panelists discuss how emerging therapies like CAR T cells and bispecific antibodies may transform frontline treatment by potentially replacing transplant or changing induction regimens, while ...

Patient-reported outcomes could have a prognostic and predictive impact on care for multiple myeloma.A retrospective analysis ...

Multiple myeloma is a rare blood cancer that is not hereditary. However, a family history of the disease may increase your risk of developing it.

Researchers at Mayo Clinic are investigating why multiple myeloma is the most common cancer in the Black community.

Multiple myeloma is a cancer of your bone marrow. Specifically, it affects your plasma cells, which are white blood cells that make antibodies to fight germs and prevent infection and disease ...